AUPH — Aurinia Pharmaceuticals Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1600620 ·
Last close
$15.40
Market Cap
$2.06B
52W High
$19.25
52W Low
$13.52
ADV30
899,112
Next earnings
2026-10-30

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 83,699,000 75,393,000 35,363,000 31,703,000 825,704,000 46,145,000 168,185,000
Jun 2026 83,220,000 76,665,000 46,341,000 37,414,000 792,262,000 179,832,000 177,398,000
Mar 2026 77,705,000 71,200,000 41,422,000 34,355,000 723,997,000 41,008,000 156,371,000
Dec 2025 77,114,000 68,315,000 33,239,000 210,794,000 751,587,000 80,213,000 170,256,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$175,243,000
Investing CF
$12,841,000
Financing CF
$-61,254,000
CapEx
$-274,000
Dividends Paid
—
Buybacks
$-83,551,000
EPS Diluted TTM
$2.29
As of
2026-11-01

Balance + Analyst (yfinance extras)

Retained Earnings
$-577,599,000
Inventory
$45,151,000
Receivables
$41,138,000
ST Investments
$263,291,000
EBIT TTM
$164,469,000
Pretax Income TTM
$160,363,000
Interest Exp TTM
$4,106,000
Analysts
7

Yahoo Snapshot (yfinance, live)

Total Revenue
$321,737,984
EBITDA
$185,420,000
Free Cash Flow
$132,733,376
Enterprise Value
$1,802,860,672
Total Cash
$486,880,000
Total Debt
$58,663,000
Shares Out
133,998,660
Trailing EPS
$2.28
Book Value
$4.91
ROE
61.4%
ROA
15.3%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 283,055,000 106,561,000 287,202,000 751,587,000 170,256,000 581,331,000 135,658,000
Dec 2024 235,133,000 18,419,000 5,752,000 550,645,000 173,167,000 377,478,000 44,388,000
Dec 2023 175,513,000 -91,691,000 -78,020,000 548,062,000 170,108,000 377,954,000 -33,461,000
Dec 2022 134,030,000 -111,470,000 -108,180,000 470,860,000 65,425,000 405,435,000 -79,529,000

TTM Snapshot

Revenues TTM
$311,507,000
NetIncome TTM
$314,114,000
OpCashFlow TTM
—
Assets (Latest)
$792,262,000
Forward EPS
$1.04

Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)

max pain strike: $22.00 · spot: $15.13 · call volume: 760 · put volume: 451
Expected Move to 2027-01-15: ±$2.05 (13.55%) — implied range $13.08 – $17.18 · ATM straddle on $15.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
IMNM Immunome Inc. $2.03B $17.18 —
PVLA PALVELLA THERAPEUTICS, INC. $2.11B $144.35 —
BHVN Biohaven Ltd. $2.00B $13.24 —
PRGO PERRIGO Co plc $2.19B $15.76 —
HRMY Harmony Biosciences Holdings, Inc. $1.94B $33.01 —

News headlines (Yahoo Finance, 1h cache)

Earnings Beat May Change The Case For Aurinia Pharmaceuticals Stock
2026-11-06 10:15 · Yahoo
Aurinia Pharmaceuticals (AUPH) Tops Q3 Earnings Estimates
2026-10-30 12:05 · Yahoo
Aurinia: Q3 Earnings Snapshot
2026-10-30 12:04 · Yahoo
Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress
2026-10-30 12:00 · Yahoo
Earnings Preview: Aurinia Pharmaceuticals (AUPH) Q3 Earnings Expected to Decline
2026-10-27 13:00 · Yahoo
How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback
2026-08-20 07:11 · Yahoo
Is Aurinia Pharmaceuticals Inc. (AUPH) A Good Stock To Buy Now?
2026-06-29 20:07 · Yahoo
AUPH Stock Rallies 6% After-Hours — Here’s Why
2026-08-19 22:15 · Yahoo
Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis
2026-07-06 12:00 · Yahoo
Earnings Preview: Ionis Pharmaceuticals (IONS) Q3 Earnings Expected to Decline
2026-10-28 13:00 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.